The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ADAMAS PHARMACEUTICALS INC | COM | 00548A106 | 711 | 100,000 | SH | SOLE | 100,000 | 0 | 0 | ||
| ALLERGAN PLC | SHS | G0177J108 | 4,392 | 30,000 | SH | SOLE | 30,000 | 0 | 0 | ||
| ANTARES PHARMA INC | COM | 036642106 | 758 | 250,000 | SH | SOLE | 250,000 | 0 | 0 | ||
| GILEAD SCIENCES INC | COM | 375558103 | 3,251 | 50,000 | SH | SOLE | 50,000 | 0 | 0 | ||
| GLAXOSMITHKLINE PLC | SPONSORED ADR | 37733W105 | 4,179 | 100,000 | SH | SOLE | 100,000 | 0 | 0 | ||
| LIGAND PHARMACEUTICALS INC | COM NEW | 53220K504 | 3,143 | 25,000 | SH | Put | SOLE | 25,000 | 0 | 0 | |
| NOVELION THERAPEUTICS INC | COM NEW | 67001K202 | 2,214 | 1,800,000 | SH | SOLE | 1,800,000 | 0 | 0 | ||
| TYME TECHNOLOGIES INC | COM | 90238J103 | 3,828 | 2,175,000 | SH | SOLE | 2,175,000 | 0 | 0 | ||
| VIKING THERAPEUTICS INC | COM | 92686J106 | 994 | 100,000 | SH | Call | SOLE | 100,000 | 0 | 0 | |
| VIKING THERAPEUTICS INC | COM | 92686J106 | 2,485 | 250,000 | SH | SOLE | 250,000 | 0 | 0 | ||